Skip to main content
. 2018 Jun 14;35(7):899–927. doi: 10.1007/s12325-018-0716-y

Table 2.

Summarized results of DACAB trial

Outcome Aspirin 100 mg (%) Ticagrelor 90 mg bd (%) Aspirin + ticagrelor (%)
SVG patency 76.5 82.8 88.7
SVG non-occlusion 80.6 86.1 89.9
Non-CABG bleeding 9 12.1 30.4
Major bleeding 0 0.6 1.2
Non-CABG and CABG bleeding 0 1.2 1.8